



*NEWS RELEASE*

FOR IMMEDIATE RELEASE

Contact: Ronald C. Trahan, APR, President, Ronald Trahan Associates Inc., +1-508-816-6730

**Stentys discloses results for world's first clinical study  
to treat acute myocardial infarction (AMI)  
with a *self-expanding* stent**

**Adaptation to vessel growth with perfect apposition  
are key take-aways of the study**

PRINCETON, N.J., and PARIS, Sept. 22, 2009—Medical device pioneer **Stentys** announced today the results on 20 patients participating in the Company's '**APPOSITION I**' **clinical study**—the world's first to treat patients with **acute myocardial infarction (AMI)** via a *self-expanding stent*. These data were disclosed today by the study's principal investigator, **Christian Spaulding, M.D., Ph.D.**, to an audience of cardiologists during a Stentys-hosted satellite meeting at the Transcatheter Cardiovascular Therapeutics ("TCT") 2009 annual scientific meeting.

"The data from the APPOSITION I study is striking on two accounts," said Prof. Spaulding, chief of interventional cardiology at Cochin Hospital, Descartes University, Paris. "First, we observed a statistically significant dilation of the vessel in the thrombotic lesion and its distality under IVUS, between treatment and three days post-procedure. Secondly, we were extremely pleased to see that the self-expanding Stentys stent remained in complete apposition with the vessel—in spite of the changing anatomy within the procedural vessel. This represents a potential breakthrough for successfully treating AMI."

"We are thrilled by the results presented today," said **Gonzague Issenmann, CEO and co-founder of Stentys**. "With 100% procedural success and no MACE reported up to 30 days, we are aggressively pursuing our APPOSITION program with the upcoming start of a randomized study of the Stentys self-expanding stent versus a balloon-expandable stent to treat AMI."

"These initial results demonstrate that a *self-expanding* stent can fully embrace the growth in vessel lumen following the relief of the acute coronary syndrome that a balloon-expandable stent is simply not engineered to do," added **Jacques Séguin, M.D., Ph.D., Chairman of Stentys**. "The next question we all need to answer is whether malapposition caused by balloon-expandable stents is acceptable."

The *self-expanding* feature of the Stentys platform, unrivaled in the stent industry, is designed to insure optimal apposition of a stent in the critical initial hours and days after an AMI procedure, by being continuously applied to the vessel's internal surface even during thrombus and vessel spasm relief—thereby avoiding *malapposition*, a significant concern to cardiologists.

**About Stentys**

Based in Princeton, N.J., and Paris, [Stentys](#) intends to make treatment of complex blocked coronary arteries as simple and effective as a conventional stenting procedure. Stentys was co-founded by [Gonzague Issenmann](#) and [Jacques Séguin, M.D., Ph.D., founder of CoreValve](#), which was acquired this year by **Medtronic for \$700 million plus earn-outs**.

#####